Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Inactivated Poliovirus Vaccine and Vaccine-Associated Paralytic Poliomyelitis-Reply

Inactivated Poliovirus Vaccine and Vaccine-Associated Paralytic Poliomyelitis-Reply In Reply. —Two recent reviews1,2 have updated our understanding of the epidemiology of VAPP in the United States and the relative proportions of recipient, contact, and immunologically abnormal cases. These data as well as a review of immunologically abnormal VAPP cases were considered by the Delphi panel.3 With respect to immunologically abnormal VAPP cases, the panel noted the following: (1) 95% of such patients were associated with B-cell disorders, and IPV administration would not be expected to induce an effective immune response in these individuals; (2) the median age at onset of paralytic disease among recipients was 11.2 months; and (3) with the exception of 1 contact case, VAPP was the precipitating event that led to the diagnosis of immunodeficiency. In addition, few cases of agammaglobulinemia (the most severe form of B-cell disorders) are diagnosed in the first year of life. In one study the mean age at diagnosis of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Inactivated Poliovirus Vaccine and Vaccine-Associated Paralytic Poliomyelitis-Reply

Inactivated Poliovirus Vaccine and Vaccine-Associated Paralytic Poliomyelitis-Reply

Abstract



In Reply.
—Two recent reviews1,2 have updated our understanding of the epidemiology of VAPP in the United States and the relative proportions of recipient, contact, and immunologically abnormal cases. These data as well as a review of immunologically abnormal VAPP cases were considered by the Delphi panel.3 With respect to immunologically abnormal VAPP cases, the panel noted the following: (1) 95% of such patients were associated with B-cell disorders, and IPV...
Loading next page...
 
/lp/american-medical-association/inactivated-poliovirus-vaccine-and-vaccine-associated-paralytic-7aWqvUHjr3

References (4)

Publisher
American Medical Association
Copyright
Copyright © 1997 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1997.03540280033019
Publisher site
See Article on Publisher Site

Abstract

In Reply. —Two recent reviews1,2 have updated our understanding of the epidemiology of VAPP in the United States and the relative proportions of recipient, contact, and immunologically abnormal cases. These data as well as a review of immunologically abnormal VAPP cases were considered by the Delphi panel.3 With respect to immunologically abnormal VAPP cases, the panel noted the following: (1) 95% of such patients were associated with B-cell disorders, and IPV administration would not be expected to induce an effective immune response in these individuals; (2) the median age at onset of paralytic disease among recipients was 11.2 months; and (3) with the exception of 1 contact case, VAPP was the precipitating event that led to the diagnosis of immunodeficiency. In addition, few cases of agammaglobulinemia (the most severe form of B-cell disorders) are diagnosed in the first year of life. In one study the mean age at diagnosis of

Journal

JAMAAmerican Medical Association

Published: Jan 22, 1997

There are no references for this article.